Cartalax Research: The Published Record and Its Limits

Published August 28, 2026 · Artemis Labs

The Cartalax (AED) research record is small, entirely preclinical, and comes from one institute. Six PubMed records name Cartalax; roughly seventeen papers test or name the AED sequence. Nearly all of them are cell-culture experiments on aging cells, published in two journals, with Vladimir Khavinson or Natalia Linkova on the author list. Two rat studies exist. No human study exists. In three papers AED was tested and was not the active peptide. This page reads the record as it is, including the parts a sales page would leave out.

Key findings

• Every primary Cartalax paper traces to the St. Petersburg Institute of Bioregulation and Gerontology. No unaffiliated laboratory has published a replication.
• The proposed mechanism for Cartalax, direct DNA binding, rests on computer docking models. The wet-lab nuclear-entry experiments tested other peptides in the family, not AED.
• In three studies AED produced no effect while a sibling peptide did. In three others the whole tissue extract matched or beat the isolated tripeptide.
• Abstracts in this literature routinely omit replicate counts, effect sizes and statistics, and most have no accessible full text.

Who produced the research?

One group. Fourteen of the primary papers appear in two journals: Advances in Gerontology, a largely Russian-language journal (Uspekhi Gerontologii), and Bulletin of Experimental Biology and Medicine. PubMed indexes six records that name Cartalax by name. Khavinson is an author on five. Every author on the sixth, a 2015 kidney study, lists the St. Petersburg institute as their affiliation (Chalisova 2015, PMID 26033601).

The one paper with Western co-authors came from the University of Chieti-Pescara in Italy, with Khavinson as senior author. In that paper the reported effect on neuronal differentiation belonged to a different peptide, KED, and to a combination, not to AED alone (Caputi 2019, PMID 30791821). Single-institute science is not wrong by definition. It is unreplicated, which is a different thing, and a reader should know which they are looking at.

What was actually measured, and in what?

Cell cultures, almost entirely. Three tissue systems appear.

Cartilage cells and stem cells. In replicatively aging human mesenchymal stem cells, AED at 200 ng/ml in the medium raised gene expression and protein synthesis of SOX9, aggrecan, type II collagen and COMP; the whole cartilage complex needed about ten times the concentration for a comparable result (Myakisheva 2023, PMID 37782646). In aging chondrocytes, AED and the cartilage complex both normalised synthesis of the SASP molecules p16, p21, p53, TNF-α, IL-1α and Sirt1, with broadly comparable effects (Myakisheva 2023, PMID 37356100).

Skin fibroblasts. Across four peptides tested on aging fibroblasts, all four inhibited MMP-9 and raised Ki-67 and CD98hc; AED and AEDG also suppressed caspase-3-dependent apoptosis (Lin’kova 2016, PMID 27259496). AED activated sirtuin-1, sirtuin-6 and collagen I synthesis, while the anti-inflammatory readout in the same study belonged to KE (Fridman 2020, PMID 33231794).

Kidney cells and explants. The largest AED dataset. In aging renal cell culture, AED and EDL increased proliferation, lowered p16, p21 and p53, and raised SIRT-6 (Khavinson 2014, PMID 25946838). T-31 activated cell renewal in renal epithelium (Khavinson 2014, PMID 24958378) and, in rat kidney explants, raised Ki-67 and lowered p53 to a lesser degree than the whole polypeptide complex (PMID 26033601).

Stem-cell gene expression. In human embryonic bone-marrow stem cells, AED, KED and KE at nanomolar concentrations raised IGF1 expression 3.5 to 5.6-fold and stimulated NF-κB expression. The FOXO1 and TNKS2 effects belonged to KED and KE. The eightfold TERT difference in that paper was a property of the aging model, not of any peptide (Ashapkin 2020, PMID 32399807).

What did the two animal studies report?

Two datasets make up the entire in-vivo record, and neither is a joint study. In old rats, AED and EDL increased urine output 1.2 to 1.4-fold (Zamorskii 2018, PMID 30607912). In a rat model of bone loss following ovary removal, both a cartilage-extract preparation and T-31 showed an effect on bone mineral density, and the extract was significantly more effective than the isolated tripeptide (Povorozniuk 2007, PMID 18306703).

That second result is part of a pattern. In kidney explants, in the bone model, and partly in the chondrocyte SASP work, the whole tissue-derived complex matched or beat the tripeptide isolated from it. The case for isolating AED from its source mixture is not settled by the group’s own data.

Is the mechanism demonstrated?

Not for Cartalax. The family hypothesis is that very short peptides cross the cell membrane and the nuclear envelope and bind DNA, regulating genes directly instead of through a receptor. The paper that assigns Cartalax a preferred DNA binding site, at the sequence acct, did so by molecular docking, a computer prediction (Khavinson 2016, PMID 27909961). A related modelling paper proposes AED forms stable minor-groove complexes (PMID 25946838). No wet-lab binding affinity, ChIP or structural data for AED-DNA interaction appears in the indexed literature.

The experiments that did test nuclear entry and DNA binding used other members of the family: fluorescence-labeled AEDG, EDR, KEDG and AEDL in HeLa cells (Fedoreyeva 2011, PMID 22117547), site-specific binding effects on endonuclease activity (Khavinson 2011, PMID 22442805), and interaction with histones (Fedoreyeva 2013, PMID 23581987). AED was not among the peptides tested in any of the three. Nuclear entry is a class-level hypothesis extended to Cartalax, not a property shown for it.

The hypothesis also has an unmeasured hardest step. An intact tripeptide would need to survive plasma proteolysis first. Unmodified native peptides are typically cleared by plasma peptidases and renal filtration within minutes unless chemically stabilised (Nordell 2026, PMID 41661442). Cartalax carries no stabilising modification, and no plasma-stability or uptake study specific to AED was located.

What the research does not show

No human evidence of any kind. A ClinicalTrials.gov search for the compound name, its sequence and the Khavinson name returned one unrelated nutrition trial. There is no registered interventional study, no human pharmacokinetics, no dose-ranging work and no toxicology data.

No independent replication. No laboratory unaffiliated with the originating institute has published on this compound.

Three nulls. In aging thymocyte cultures only AB-9 was active; AED was not (Lin’kova 2011, PMID 22238759). In cisplatin-induced kidney injury the protective effect belonged to EDL (Zamorskii 2015, PMID 26515176). In neuronal differentiation the GAP43 increase was attributed to KED and the combination (PMID 30791821).

No telomerase effect. The TERT figure sometimes attached to AED was a difference between two aging models (PMID 32399807).

No place in the group’s own synthesis. When the same researchers reviewed peptides that steer stem cells toward cartilage in 2023, they named nine candidates. AED was not one of them (Linkova 2023, PMID 37176122).

Frequently asked questions

How many studies are there?

Six PubMed records name Cartalax. Roughly seventeen test or name the AED sequence. A raw search for “Ala-Glu-Asp” returns about a hundred, most of which concern the tetrapeptide AEDG; the Cartalax vs Epitalon page explains that mix-up.

Are the concentrations in these papers doses?

No. Figures like 200 ng/ml are the concentration of peptide in a culture dish, reported by the authors as an experimental condition. They describe cells, not organisms.

Why does Artemis Labs sell a compound with this little evidence?

Because researchers ask for it and the data that exists is real. The Cartalax product page carries the same counter-evidence section this page does. We would rather list the compound with an honest record than let a page imply strength that is not there.

What would change this assessment?

An independent replication from an unaffiliated laboratory, a wet-lab measurement of AED-DNA binding, or any registered human study. None exists as of the date above.

References

1. Myakisheva SN et al. Advances in Gerontology. 2023. PMID 37782646
2. Myakisheva SN et al. Advances in Gerontology. 2023. PMID 37356100
3. Fridman NV et al. Bulletin of Experimental Biology and Medicine. 2020. PMID 33231794
4. Lin’kova NS et al. Bulletin of Experimental Biology and Medicine. 2016. PMID 27259496
5. Ashapkin V et al. Molecular Biology Reports. 2020. PMID 32399807
6. Khavinson VK et al. Bulletin of Experimental Biology and Medicine. 2016. PMID 27909961
7. Khavinson VKh et al. Advances in Gerontology. 2014. PMID 25946838
8. Chalisova NI et al. Bulletin of Experimental Biology and Medicine. 2015. PMID 26033601
9. Khavinson VKh et al. Bulletin of Experimental Biology and Medicine. 2014. PMID 24958378
10. Zamorskii II et al. Advances in Gerontology. 2018. PMID 30607912
11. Povorozniuk VV et al. Advances in Gerontology. 2007. PMID 18306703
12. Fedoreyeva LI et al. Biochemistry (Moscow). 2011. PMID 22117547
13. Khavinson VKh et al. Bulletin of Experimental Biology and Medicine. 2011. PMID 22442805
14. Fedoreyeva LI et al. Biochemistry (Moscow). 2013. PMID 23581987
15. Lin’kova NS et al. Bulletin of Experimental Biology and Medicine. 2011. PMID 22238759
16. Zamorskii II et al. Bulletin of Experimental Biology and Medicine. 2015. PMID 26515176
17. Caputi S et al. International Journal of Immunopathology and Pharmacology. 2019. PMID 30791821
18. Linkova N et al. International Journal of Molecular Sciences. 2023. PMID 37176122
19. Nordell P et al. Clinical Pharmacokinetics. 2026. PMID 41661442

Methodology: every PMID above was re-verified through NCBI E-utilities on August 28, 2026; findings are transcribed from the Artemis Labs Cartalax record, which was built from the indexed abstracts. Where an abstract attributes a result to a peptide other than AED, this page says so.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.